influenza
virus
b
rna
virus
orthomyxovirida
famili
combat
pathogen
virus
season
influenza
vaccin
formul
annual
vaccin
recommend
cdc
everybodi
mo
older
flu
season
flu
season
cdc
estim
million
dose
influenza
vaccin
distribut
unit
state
despit
avail
season
vaccin
annual
estim
mortal
influenza
rang
death
peak
influenza
circul
popul
vaccin
protect
circul
strain
influenza
close
match
vaccin
strain
fact
mani
peopl
get
immun
explain
statist
importantli
season
influenza
vaccin
protect
newli
emerg
strain
could
potenti
caus
larg
outbreak
pandem
futur
addit
mortal
morbid
associ
viral
infect
coinfect
exacerb
outcom
influenza
infect
exemplifi
pandem
death
due
secondari
bacteri
pneumonia
secondari
bacteri
infect
influenza
infect
account
signific
number
death
worldwid
therefor
would
valuabl
aid
public
health
therapeut
option
treat
individu
unmet
need
influenza
season
circul
influenza
strain
drift
variant
season
vaccin
strain
result
vaccin
reduc
efficaci
nonimmun
individu
first
barrier
influenza
infect
cell
innat
immun
system
cell
capabl
recogn
invad
viru
innat
recognit
essenti
initi
adapt
immun
respons
accord
theori
cell
innat
immun
system
identifi
pathogen
protein
call
receptor
protein
identifi
molecular
pattern
present
invad
microorgan
case
influenza
infect
cytosol
rna
helicas
import
role
recognit
trigger
product
protect
proinflammatori
cytokin
antivir
type
ifn
theoriz
host
cell
distinguish
viral
rna
cellular
rna
panhandl
structur
terminu
howev
influenza
protein
capabl
antagon
signal
highlight
need
redund
innat
immun
recognit
also
recogn
viral
rna
shown
activ
respons
influenza
infect
human
lung
epitheli
cell
induc
proinflammatori
cytokin
certain
cell
type
plasmacytoid
dendrit
cell
also
recogn
influenza
genom
rna
innat
immun
recognit
occur
exclus
recognit
pathogen
substructur
influenza
infect
induc
cellular
stress
lead
mitochondri
dysfunct
culmin
activ
lead
releas
proinflammatori
mediat
infect
cell
also
releas
damp
alert
neighbor
cell
danger
produc
vitro
infect
influenza
viru
wherea
damp
releas
vivo
influenza
infect
mice
human
reactiv
oxygen
speci
releas
cell
lung
human
anim
viral
infect
caus
oxid
endogen
phospholipid
produc
oxid
phosphatidylcholin
importantli
oxid
phospholipid
shown
signal
relevantli
report
mice
resist
infect
influenza
viru
strain
well
potent
strain
antagonist
eritoran
eisai
co
tokyo
japan
block
lethal
clinic
symptom
caus
infect
given
start
infect
block
signal
infect
ab
also
confer
protect
antagonist
identifi
group
indic
antagonist
may
repres
novel
class
drug
use
treat
patient
influenza
defensin
small
cation
peptid
primarili
serv
innat
immun
defens
mechan
infecti
microorgan
unlik
circular
form
ligat
truncat
precursor
peptid
possess
broad
antimicrobi
activ
target
bacteria
virus
fungi
human
deft
pseudogen
contain
prematur
stop
codon
prevent
translat
howev
peptid
synthesi
allow
research
construct
artifici
human
call
rc
individu
rc
vari
slightli
noncystein
amino
residu
bind
high
affin
glycosyl
protein
hiv
prevent
fusion
mediat
influenza
hemagglutinin
consequ
rc
effect
prevent
vitro
infect
human
cell
line
either
hiv
influenza
viru
similarli
rc
protect
vitro
bind
surfac
glycoprotein
addit
role
fight
microorgan
defensin
might
also
key
regulatori
role
limit
inflamm
human
inhibit
signal
vitro
vivo
rtd
prevent
cytokin
secret
human
blood
leukocyt
treat
multipl
tlr
ligand
includ
agonist
lp
demonstr
also
regul
host
respons
mediat
cellular
glycoprotein
also
suggest
role
structur
similar
rc
tlr
antagon
clinic
rc
could
repres
novel
therapeut
influenza
infect
inhibit
detriment
product
cytokin
block
infect
viru
coinfect
bacteria
aim
studi
determin
whether
could
inhibit
signal
whether
could
use
therapeut
diseas
contain
substitut
parent
rc
peptid
made
synthesi
backbon
cycliz
achiev
intramolecular
nativ
chemic
ligat
linear
peptid
synthes
solid
phase
use
boc
chemistri
disulfid
bond
form
oxid
condit
presenc
dmso
peptid
purifi
hplc
homogen
puriti
verifi
electrospray
ioniz
mass
spectrometri
final
product
shown
supplement
fig
analyz
hplc
water
milford
usa
xbridg
column
mm
run
gradient
acetonitril
contain
trifluoroacet
acid
flow
rate
mlmin
observ
molecular
mass
da
within
experiment
error
expect
valu
da
calcul
base
averag
isotop
composit
peptid
solubil
pb
use
escherichia
coli
lp
prepar
describ
escherichia
coli
label
biotin
tag
invivogen
san
diego
ca
usa
dmxaa
st
loui
mo
usa
synthet
triacyl
lipoprotein
invivogen
invivogen
recombin
mous
ebiosci
san
diego
ca
usa
purchas
indic
vendor
mous
mab
use
visual
protein
tag
flag
clone
ecfp
clone
origen
technolog
rockvil
md
usa
western
blot
analysi
ab
cell
signal
technolog
danver
usa
use
visual
polyclon
ab
previous
describ
primari
secondari
ab
use
studi
previous
describ
lal
chromogen
endotoxin
quantit
kit
thermo
fisher
scientif
waltham
usa
use
accord
manufactur
instruct
test
biolog
activ
e
coli
lp
includ
kit
posit
control
control
standard
endotoxin
e
coli
purchas
associ
cape
cod
inc
east
falmouth
usa
use
accord
manufactur
instruct
measur
abil
antagon
biolog
activ
lp
dose
higher
euml
recombin
protein
kindli
provid
dr
kevin
tracey
feinstein
institut
medic
research
manhasset
ny
usa
mice
kindli
provid
dr
donald
cook
us
nation
institut
health
bethesda
md
usa
mice
obtain
lilli
research
laboratori
indianapoli
usa
first
enzym
recruit
behav
similarli
mice
n
background
origin
obtain
dr
shizuo
akira
osaka
univers
osaka
japan
breed
univers
maryland
baltimor
md
usa
mous
periton
isol
wt
jackson
laboratori
bar
harbor
usa
cultur
previous
describ
human
matur
elutri
pbmc
healthi
donor
previous
describ
mous
human
pretreat
either
pb
control
within
stimul
vitro
infect
perform
previous
describ
lysat
harvest
indic
time
tripur
roch
diagnost
north
america
indianapoli
usa
subsequ
gene
express
analysi
cdna
synthes
rna
previous
describ
reaction
monitor
fast
pcr
system
thermo
fisher
scientif
use
power
sybr
green
mix
pcr
master
mix
thermo
fisher
scientif
individu
gene
analyz
cytokin
human
mous
primer
previous
publish
total
amount
mrna
calcul
use
compar
cycl
threshold
method
express
compar
untreat
uninfect
cell
cell
grown
dmem
supplement
mm
uml
penicillin
streptomycin
fc
previous
describ
one
night
transfect
cell
plate
dish
follow
day
cell
transfect
express
plasmid
use
transfect
reagent
superfect
qiagen
valencia
ca
usa
accord
manufactur
suppli
instruct
specif
total
plasmid
empti
vector
mix
superfect
ratio
dual
transfect
plasmid
use
amount
superfect
kept
constant
transfect
cell
allow
incub
growth
medium
h
monitor
transgen
express
h
cell
wash
twice
pb
lyse
mm
hepe
triton
mm
nacl
mm
pmsf
lysat
incub
ice
min
centrifug
rpm
min
pellet
cellular
debri
supernat
withdrawn
analyz
western
blot
directli
input
sampl
immunoprecipit
latter
case
lysat
incub
overnight
gentl
rotat
presenc
ab
protein
g
agaros
thermo
fisher
scientif
bead
slurri
ad
mixtur
incub
min
constant
rotat
room
temperatur
bead
harvest
centrifug
wash
time
bind
buffer
mm
tri
mm
nacl
ph
harvest
bound
protein
bead
resuspend
laemmli
buffer
vortex
boil
min
centrifug
supernat
separ
gel
transfer
polyvinyl
difluorid
membran
lp
pulldown
incub
min
room
temperatur
presenc
absenc
excess
unlabel
e
coli
lp
pierc
streptavidin
ultralink
resin
bead
slurri
thermo
fisher
scientif
ad
sampl
incub
min
constant
rotat
room
temperatur
bead
harvest
centrifug
wash
time
bind
buffer
phosphat
nacl
ph
harvest
bound
protein
bead
resuspend
laemmli
buffer
vortex
boil
min
centrifug
supernat
withdrawn
serial
dilut
sampl
onto
nitrocellulos
membran
pore
size
air
dri
block
incub
parallel
h
probe
biotin
overnight
probe
mous
protocol
approv
institut
anim
care
use
committe
univers
maryland
baltimor
femal
wt
mice
infect
intranas
describ
mice
inject
daili
postinfect
iv
salin
similar
dose
regimen
antagonist
eritoran
previous
shown
protect
mice
infect
mice
monitor
daili
surviv
clinic
score
weight
loss
clinic
score
rang
symptom
moribund
includ
piloerect
hunch
postur
ruffl
fur
audibl
lung
crackl
lethargi
previous
detail
mice
euthan
soon
becam
moribund
prevent
suffer
anim
experi
perform
duplic
analysi
gene
express
numer
valu
obtain
assay
analyz
graphpad
prism
graphpad
softwar
la
jolla
ca
usa
either
anova
depend
number
experiment
variabl
signific
determin
p
anova
tukey
post
hoc
test
use
look
signific
among
experiment
group
within
data
set
surviv
curv
mice
analyz
signific
test
supplement
materi
articl
includ
figur
supplement
fig
show
peptid
sequenc
repres
exampl
puriti
peptid
synthesi
rtd
shown
decreas
cytokin
secret
respons
multipl
tlr
agonist
structur
similar
rtd
hypothes
would
antagon
signal
lead
cytokin
induct
consist
predict
inhibit
manner
fig
induct
decreas
presenc
earli
min
lp
treatment
fig
signal
transduct
respons
lp
initi
homodimer
signal
transduct
contain
uniqu
bifurc
use
trif
adaptor
protein
consid
gene
induc
downstream
pathway
contrast
repres
cytokin
determin
whether
pathway
also
affect
treatment
express
gene
analyz
inhibit
fig
albeit
lesser
extent
evid
mrna
determin
whether
antagon
respons
primari
human
also
stimul
lp
presenc
similar
observ
mous
also
inhibit
cytokin
gene
express
respons
lp
stimul
fig
decreas
cytokin
gene
express
treatment
correl
block
phosphoryl
signal
element
min
lp
stimul
fig
similarli
activ
mapk
pathway
erk
jnk
also
decreas
time
point
presenc
fig
phosphoryl
remain
decreas
min
lp
treatment
presenc
fig
wherea
phosphoryl
mapk
increas
time
point
fig
indic
blockad
delay
signal
transduct
dose
lp
ablat
entir
inhibit
signal
human
mous
cell
could
possibl
explain
sequestr
lp
host
signal
complex
sought
test
possibl
system
biolog
activ
lp
measur
lal
assay
presenc
absenc
determin
whether
cytokin
express
result
like
due
interact
lp
biolog
activ
endotoxin
uml
ngml
lp
partial
inhibit
almost
complet
inhibit
fig
dose
lp
use
lal
assay
repres
lower
dose
lp
use
stimul
eg
see
fig
test
dose
lp
use
differ
lal
assay
linear
rang
euml
maintain
dose
condit
strongli
inhibit
biolog
activ
lp
dose
test
includ
euml
fig
also
inhibit
lal
activ
biotinyl
lp
dose
rang
ngml
fig
suggest
like
inhibit
signal
part
sequestr
lp
examin
possibl
perform
vitro
pulldown
assay
biotinyl
lp
presenc
absenc
impair
abil
streptavidin
bead
pull
fig
addit
recov
upon
pulldown
biotinyl
lp
streptavidin
bead
suggest
direct
bind
lp
fig
verifi
bind
specif
excess
unlabel
lp
e
coli
also
ad
mix
pulldown
excess
unlabel
lp
prevent
pulldown
biotinyl
lp
suggest
bind
lp
specif
fig
contrast
interact
lp
pull
biotinyl
agonist
fig
although
data
show
evid
may
mediat
inhibit
signal
though
sequestr
lp
must
note
even
inhibit
lp
activ
sequestr
might
affect
cytokin
express
system
lp
dose
use
stimul
ngml
linear
portion
cytokin
curv
fig
b
reason
also
sought
explor
capac
disrupt
dimer
use
model
oligomer
occur
absenc
ligand
laboratori
previous
shown
overexpress
cell
facilit
signal
absenc
lp
cotransfect
induc
physic
interact
construct
evidenc
coimmunoprecipit
epitop
tag
fig
use
model
examin
whether
could
destabil
interact
addit
fail
inhibit
coimmunoprecipit
fig
describ
inhibitori
role
signal
transduct
sought
test
whether
role
similar
innat
immun
signal
pathway
cytokin
secret
shown
regul
rtd
human
blood
leukocyt
might
expect
regul
similar
laboratori
also
inhibit
proinflammatori
gene
induct
mous
fig
b
demonstr
inhibit
restrict
howev
fail
bind
biotinyl
fig
therefor
inhibit
signal
restrict
agonist
bind
directli
determin
degre
pathway
specif
inhibit
mous
also
stimul
agonist
absenc
presenc
fail
inhibit
cytokin
gene
induct
respons
either
recombin
dmxaa
fig
dmxaa
potent
induc
mous
intracellular
activ
sting
unlik
initi
signal
extracellularli
note
appar
lack
induct
respons
lp
fig
due
suboptim
time
point
express
see
fig
collect
latter
result
demonstr
univers
inhibitor
innat
immun
signal
pathway
recent
discoveri
eritoran
protect
mice
lethal
infect
suggest
treatment
mice
antagonist
may
also
protect
lethal
influenza
infect
effect
infect
first
examin
vitro
infect
model
wt
infect
h
vitro
inhibit
express
proinflammatori
gene
encod
fig
b
although
secret
shown
partial
depend
observ
induct
mrna
significantli
impair
h
postinfect
fig
similarli
induc
similar
amount
mrna
respons
wt
control
fig
f
first
kinas
recruit
signal
transduct
behav
compar
suggest
damp
activ
signal
vivo
like
present
vitro
model
time
point
test
result
also
indic
influenc
cytokin
induct
vitro
infect
independ
possibl
inhibit
signal
receptor
also
capabl
recogn
damp
shown
releas
influenza
infect
mice
human
importantli
also
known
activ
signal
suppress
cytokin
gene
induct
respons
fig
h
demonstr
also
block
gene
express
mediat
damp
determin
whether
could
use
antivir
andor
therapeut
vivo
mice
infect
given
daili
iv
inject
start
h
infect
continu
postinfect
previous
report
eritoran
protect
mice
use
ident
dose
regimen
studi
treatment
mice
also
protect
lethal
fig
significantli
lessen
clinic
symptom
fig
latter
signific
decreas
clinic
symptom
suggest
mere
delay
time
death
survivor
typic
healthi
end
wk
time
drug
administr
hypothes
mediat
effect
block
initi
uptak
viru
togeth
data
suggest
strong
candid
futur
human
clinic
trial
search
novel
viral
therapeut
although
innat
immun
system
crucial
role
initi
immun
respons
invad
microorgan
overexuber
signal
may
actual
contribut
patholog
infect
sword
effect
inflamm
respons
innat
immun
signal
illustr
infect
influenza
viru
tlr
adaptor
requir
mous
surviv
infect
illustr
benefici
role
innat
signal
pathway
pretreat
mice
agonist
vivo
infect
influenza
shown
protect
howev
time
signal
pathway
crucial
oxid
stress
lung
infect
link
develop
oxid
phospholipid
damp
mediat
acut
lung
injuri
detriment
role
inflamm
exacerb
bacteri
coinfect
role
infect
mice
refractori
lethal
associ
infect
support
role
oxid
phospholipid
mediat
lethal
mortal
prevent
inhibit
oxid
phospholipid
format
administ
antioxid
cystein
addit
report
mortal
prevent
inhibit
signal
infect
potent
synthet
antagonist
eritoran
ab
agent
block
signal
thu
hypothes
drug
target
signal
pathway
could
potenti
function
novel
therapi
studi
fulli
capabl
inhibit
signal
mous
human
impair
pathway
suggest
could
function
prevent
initi
interact
lp
either
sequestr
lp
blockad
signal
event
base
studi
rule
strong
possibl
signific
part
inhibit
mediat
lp
sequestr
signal
complex
could
bind
lp
vitro
pulldown
assay
inhibit
broad
rang
lp
bioactiv
lal
assay
howev
dose
lp
use
stimul
studi
satur
rang
strong
antagonist
would
expect
signific
effect
cytokin
gene
express
signal
transduct
respons
lp
initi
plasma
membran
homodimer
molecul
ectodomain
human
contain
glycosyl
site
requir
express
function
remov
sialic
acid
residu
increas
signal
suggest
sialic
residu
may
interfac
dimer
rc
bind
high
affin
protein
exhibit
glycosyl
hypothes
could
antagon
signal
bind
glycan
prevent
dimer
line
theori
human
also
inhibit
signal
direct
bind
use
model
oligomer
cell
test
whether
could
prevent
disrupt
homotyp
interact
addit
fail
disrupt
oligom
assay
could
mean
target
directli
bind
site
unavail
conform
unfortun
could
decreas
input
concentr
plasmid
use
transfect
level
permit
signal
would
still
permit
detect
coimmunoprecipit
molecul
protein
crucial
part
lp
recognit
complex
also
glycosyl
also
possibl
might
primari
target
pathway
addit
inhibit
signal
also
found
activ
signal
inhibit
contrast
direct
interact
lp
unabl
interact
vitro
suggest
capac
act
way
sole
ligand
sequestr
human
also
contain
glycosyl
site
could
put
target
altern
signal
transduct
sensit
architectur
microdomain
addit
phosphatidylserin
speci
impair
signal
pathway
given
posit
charg
found
bind
anion
membran
dipalmitoyl
phosphatidylglycerol
tempt
specul
abil
block
signal
caus
effect
cell
membran
howev
mechan
seem
less
like
signal
also
requir
receptor
oligomer
perturb
fusion
protein
respiratori
syncyti
viru
recogn
manner
influenza
protein
identifi
function
ligand
contrast
damp
releas
vivo
infect
signal
less
clear
whether
damp
produc
vitro
much
effect
gene
regul
secret
proinflammatori
gene
h
postinfect
shown
bone
periton
howev
protein
secret
h
decreas
absenc
exhibit
partial
depend
data
use
indic
differ
cytokin
product
mediat
lack
signal
due
defect
transcript
gene
h
postinfect
part
role
innat
immun
adaptor
protein
also
shown
involv
stabil
mrna
speci
contain
element
common
mani
cytokin
surmis
pathway
may
mediat
effect
cytokin
secret
respons
alter
mrna
stabil
alter
transcript
rc
offer
potenti
limit
inflamm
mediat
damp
also
target
viru
although
may
act
block
initi
viral
entri
previous
describ
shown
less
effect
influenza
strain
instanc
preincub
viru
variou
differ
rc
min
achiev
decreas
viral
infect
measur
fluoresc
focu
format
assay
importantli
none
experi
featur
preincub
viru
would
limit
abil
block
viru
directli
proof
concept
rc
use
therapeut
test
mous
model
influenza
infect
treatment
start
postinfect
shown
lessen
sever
diseas
result
highli
signific
increas
surviv
fig
result
inhibit
cytokin
express
consist
possibl
antagon
signal
account
least
part
protect
mice
protect
therapeut
effect
similar
previous
report
antagonist
eritoran
suggest
may
act
vivo
least
partial
antagon
howev
rule
possibl
addit
direct
effect
viru
observ
other
although
eritoran
directli
kill
influenza
vitro
eritoran
therapi
associ
decreas
influenza
titer
vivo
infect
highlight
import
connect
inflamm
viral
replic
infect
model
quit
possibl
effect
system
antivir
overal
result
mous
model
especi
encourag
strain
use
studi
lack
glycosyl
hemagglutinin
protein
make
resist
influenza
strain
vitro
therefor
would
predict
effect
human
strain
increas
glycosyl
similar
efficaci
demonstr
studi
rtd
protect
mice
lethal
lung
infect
sever
acut
respiratori
limit
potenti
overexuber
cytokin
respons
occur
lung
togeth
data
suggest
defensin
specif
strong
candid
futur
human
clinic
trial
search
novel
viral
therapeut
dp
design
coordin
experi
studi
perform
analyz
experi
wrote
manuscript
ka
design
perform
experi
outlin
fig
w
lai
provid
technic
assist
involv
infect
describ
fig
w
lu
provid
technic
assist
figur
synthes
amc
provid
technic
assist
detect
western
blot
fig
snv
help
design
concept
experi
analysi
data
draft
manuscript
agd
conceiv
studi
help
draft
manuscript
author
review
result
approv
final
version
manuscript
author
declar
conflict
interest
content
manuscript
sole
respons
author
necessarili
repres
offici
view
nation
institut
health
nation
institut
allergi
infecti
diseas
